AstraZeneca Reports P-III Trial (FLAURA2) Results of Tagrisso for EGFR-Mutated Advanced Lung Cancer
- The P-III trial evaluating Tagrisso (80mg, qd) + CT (pemetrexed (500mg/m2) + cisplatin (75mg/m2) or carboplatin) vs Tagrisso alone in 557 patients with LA (Stage IIIB-IIIC) or metastatic (Stage IV) EGFRm NSCLC in 150+ centers across 20+ countries, incl. in the US, EU, South America & Asia
- The results showed an improvement in PFS & a 38% reduction in risk of disease progression or death. By investigator assessment & BICR for Tagrisso monotx. and Tagrisso + CT, m-PFS (16.7 and 25.5mos.) & (19.9 and 29.4mos.), respectively, PFS benefit was observed across all prespecified subgroups
- The OS data were immature & a favorable trend was observed for Tagrisso + CT. The safety results & discontinuation rates due to AEs were consistent with the established profiles of each medicine with no new safety concerns, grade ≥3 AEs (64% vs 27%)
Ref: Astrazenneca | Image: Astrazenneca
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at firstname.lastname@example.org
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at email@example.com.